



Source: CVS Health, "Gene Therapy: Keeping Costs from Negating Its Unprecedented Potential", (2020). Available at: http://bit.ly/2W2eh3W.
False
Gene therapies (including CAR-T) could add $45 billion to US healthcare costs over the next five years, CVS Health report finds
Source: CVS Health, "Gene Therapy: Keeping Costs from Negating Its Unprecedented Potential", (2020). Available at: http://bit.ly/2W2eh3W.
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
False
False
November 7, 2014
0 min read
Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.
April 2, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
April 1, 2025
3 min read
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
April 1, 2025
9 min read
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.
False